Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
16
|
pubmed:dateCreated |
1984-10-3
|
pubmed:abstractText |
A competition radioimmunoassay was developed, utilizing a murine monoclonal antibody to human pancreatic adenocarcinoma cells. Immunoblotting of a standard antigen preparation from either serum or ascites fluid after electrophoresis in 1% agarose showed that the specific DU-PAN-2 activity resided in two major high molecular weight bands. DU-PAN-2 antigen levels were expressed as arbitrary units based on a standard partially purified antigen preparation. The inhibition curve with standard antigen was reproducible (SD less than 10%) and essentially linear from 25 to 200 units/ml. The mean DU-PAN-2 antigen concentration for the sera from 126 normal individuals was 81 units/ml. Sera from pediatric patients with malignancy had a mean of 127 units/ml, while nasopharyngeal, stage III melanoma, and ovarian carcinoma patients had means of 89, 92, and 119 units/ml, respectively. All values in normal subjects as well as the melanoma, nasopharyngeal, ovarian, and pediatric cancer patients were less than 400 units/ml. Intermediate antigen levels were detected in patients with alimentary tract malignancies. Eight of 20 gastric cancer and 8 of 76 colorectal carcinoma patients and 3 patients with benign or nonmalignant gastrointestinal tract disease had DU-PAN-2 values exceeding 400 units/ml. Ascites fluids from 6/6 and pancreatic juice from 2/2 pancreatic cancer patients had values greater than 750 units/ml. Serum from 68% of the 89 pancreatic cancer patients tested had DU-PAN-2 antigen levels greater than 400 units/ml. The mean serum value in this patient population was 4888 units/ml.
|
pubmed:grant | |
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6591188-5126927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6591188-5432063,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6591188-603621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6591188-6163212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6591188-6193872,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6591188-6371347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6591188-7034925
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0027-8424
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
81
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5242-6
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:6591188-Adenocarcinoma,
pubmed-meshheading:6591188-Antigens, Neoplasm,
pubmed-meshheading:6591188-Electrophoresis, Agar Gel,
pubmed-meshheading:6591188-Humans,
pubmed-meshheading:6591188-Neoplasms,
pubmed-meshheading:6591188-Pancreatic Neoplasms,
pubmed-meshheading:6591188-Radioimmunoassay,
pubmed-meshheading:6591188-Reference Values
|
pubmed:year |
1984
|
pubmed:articleTitle |
Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|